Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief Financial Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,003 |
Ending reported balance
After 2026-09-30 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 9,229 · Balance 68,232 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Row 2 · 2026-09-30 · Exercise / conversion · Acquired 28,438 · Balance 96,670 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Row 3 · 2026-09-30 · Exercise / conversion · Acquired 15,650 · Balance 112,320 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Row 4 · 2026-09-30 · Exercise / conversion · Acquired 5,312 · Balance 117,632 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Row 5 · 2026-09-30 · Sale · Disposed 12,595 · Balance 105,037 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 6 · 2026-09-30 · Sale · Disposed 46,034 · Balance 59,003 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.98 · Expires 2035-01-01 | Direct | 29,291 |
Reported balance
After 2026-09-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-30 · Exercise / conversion · Disposed 9,229 · Balance 29,291 F4: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2034-01-01 | Direct | 49,562 |
Reported balance
After 2026-09-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-30 · Exercise / conversion · Disposed 28,438 · Balance 49,562 F5: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.19 · Expires 2032-04-17 | Direct | 51,150 |
Reported balance
After 2026-09-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-30 · Exercise / conversion · Disposed 15,650 · Balance 51,150 F6: The stock option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.17 · Expires 2033-01-15 | Direct | 25,235 |
Reported balance
After 2026-09-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-30 · Exercise / conversion · Disposed 5,312 · Balance 25,235 F7: The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
F5: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
F6: The stock option is fully vested.
F7: The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 5,312 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · derivative · entry 10 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,235 Underlying: Common Stock · 5,312 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 15,650 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · derivative · entry 9 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,150 Underlying: Common Stock · 15,650 shares Expires 2032-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 28,438 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · derivative · entry 8 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,562 Underlying: Common Stock · 28,438 shares Expires 2034-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 9,229 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · derivative · entry 7 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,291 Underlying: Common Stock · 9,229 shares Expires 2035-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 46,034 | $141.78 | $6,526,700.52 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · nonDerivative · entry 6 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,003 F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 12,595 | $141.77 | $1,785,593.15 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · nonDerivative · entry 5 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,037 F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 5,312 | $12.17 | $64,647.04 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · nonDerivative · entry 4 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 15,650 | $19.19 | $300,323.50 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · nonDerivative · entry 3 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 28,438 | $23.42 | $666,017.96 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 9,229 | $38.98 | $359,746.42 |
DisclosureSEC source: 0001104659-26-113279 · tm2626857-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:58 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 1,750 | $105.47 | $184,572.50 |
DisclosureSEC source: 0001104659-26-046110 · tm2612380-2_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,003 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 5,265 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-26-036317 · tm2610129-1_4seq1.xml · derivative · entry 5 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,282 Underlying: Common Stock · 5,265 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001104659-26-036317 · tm2610129-1_4seq1.xml · derivative · entry 4 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,300 Underlying: Common Stock · 19,500 shares Expires 2032-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 24,765 | $104.24 | $2,581,503.60 |
DisclosureSEC source: 0001104659-26-036317 · tm2610129-1_4seq1.xml · nonDerivative · entry 3 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,753 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $104.00 to $104.465. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 5,265 | $12.17 | $64,075.05 |
DisclosureSEC source: 0001104659-26-036317 · tm2610129-1_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 19,500 | $19.19 | $374,205.00 |
DisclosureSEC source: 0001104659-26-036317 · tm2610129-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-26-007128 · tm264253-2_4seq1.xml · derivative · entry 6 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,547 Underlying: Common Stock · 12,000 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001104659-26-007128 · tm264253-2_4seq1.xml · derivative · entry 5 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,800 Underlying: Common Stock · 16,000 shares Expires 2032-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 18,203 | $83.14 | $1,513,397.42 |
DisclosureSEC source: 0001104659-26-007128 · tm264253-2_4seq1.xml · nonDerivative · entry 4 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,320 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.80 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 28,000 | $83.13 | $2,327,640.00 |
DisclosureSEC source: 0001104659-26-007128 · tm264253-2_4seq1.xml · nonDerivative · entry 3 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,523 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.77 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 12,000 | $12.17 | $146,040.00 |
DisclosureSEC source: 0001104659-26-007128 · tm264253-2_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 16,000 | $19.19 | $307,040.00 |
DisclosureSEC source: 0001104659-26-007128 · tm264253-2_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 446 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2025. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 22:15 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 8,588 | $82.48 | $708,338.24 |
DisclosureSEC source: 0001104659-26-005440 · tm263774-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,077 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:37 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $87.18 | $0.00 |
DisclosureSEC source: 0001104659-26-001472 · tm262304-2_4seq1.xml · derivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:37 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 25,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001472 · tm262304-2_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,665 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| April 22, 2025 Filed Apr 23, 2025 20:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 1,756 | $46.00 | $80,776.00 |
DisclosureSEC source: 0001104659-25-038036 · tm2513020-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,065 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 9,700 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · derivative · entry 5 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,800 Underlying: Common Stock · 9,700 shares Expires 2032-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 15,203 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · derivative · entry 4 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,547 Underlying: Common Stock · 15,203 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 24,903 | $58.73 | $1,462,553.19 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · nonDerivative · entry 3 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,821 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.12 to $59.235. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 9,700 | $19.19 | $186,143.00 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 15,203 | $12.17 | $185,020.51 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 22:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 2,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004569 · tm253633-1_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,821 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 22:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 1,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004569 · tm253633-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,422 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:05 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 38,520 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001426 · tm252003-1_4seq1.xml · derivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,520 Underlying: Common Stock · 38,520 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:05 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 31,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001426 · tm252003-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,739 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-24-099838 · tm2423879-2_4seq1.xml · derivative · entry 6 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 6,000 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001104659-24-099838 · tm2423879-2_4seq1.xml · derivative · entry 5 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,500 Underlying: Common Stock · 6,000 shares Expires 2032-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 12,000 | $44.47 | $533,640.00 |
DisclosureSEC source: 0001104659-24-099838 · tm2423879-2_4seq1.xml · nonDerivative · entry 4 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,960 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.43 to $44.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 6,000 | $12.17 | $73,020.00 |
DisclosureSEC source: 0001104659-24-099838 · tm2423879-2_4seq1.xml · nonDerivative · entry 3 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 6,000 | $19.19 | $115,140.00 |
DisclosureSEC source: 0001104659-24-099838 · tm2423879-2_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 2,203 | $44.59 | $98,231.77 |
DisclosureSEC source: 0001104659-24-099838 · tm2423879-2_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,960 Read SEC document |
| April 18, 2024 Filed Apr 20, 2024 00:05 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 1,234 | $25.11 | $30,985.74 |
DisclosureSEC source: 0001104659-24-049567 · tm2412317-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,163 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-24-030156 · tm247765-1_4seq1.xml · derivative · entry 6 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,750 Underlying: Common Stock · 12,000 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 2,248 | $32.33 | $72,677.84 |
DisclosureSEC source: 0001104659-24-030156 · tm247765-1_4seq1.xml · nonDerivative · entry 5 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,397 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 12,000 | $32.22 | $386,640.00 |
DisclosureSEC source: 0001104659-24-030156 · tm247765-1_4seq1.xml · nonDerivative · entry 4 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,645 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.17 to $32.31. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 12,000 | $12.17 | $146,040.00 |
DisclosureSEC source: 0001104659-24-030156 · tm247765-1_4seq1.xml · nonDerivative · entry 3 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 2,089 | $31.00 | $64,759.00 |
DisclosureSEC source: 0001104659-24-030156 · tm247765-1_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,645 Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 7,850 | $30.61 | $240,288.50 |
DisclosureSEC source: 0001104659-24-030156 · tm247765-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,734 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.57 to $30.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2024 Filed Jan 19, 2024 01:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 1,452 | $24.63 | $35,762.76 |
DisclosureSEC source: 0001104659-24-004899 · tm243616-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,584 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 3,541 restricted stock units on January 15, 2024. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:07 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 78,000 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-24-001489 · tm241954-1_4seq1.xml · derivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2034-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.